Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic and molecular remissions. However, approximately 15–20% fail to obtain optimal responses ac...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer
Hlavní autoři: Massimino, Michele, Stella, Stefania, Tirrò, Elena, Romano, Chiara, Pennisi, Maria Stella, Puma, Adriana, Manzella, Livia, Zanghì, Antonino, Stagno, Fabio, Di Raimondo, Francesco, Vigneri, Paolo
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817805/
https://ncbi.nlm.nih.gov/pubmed/29455672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0805-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky